50 Participants Needed

IMGN853 for Endometrial Cancer

LB
Alessandro Santin, MD < Yale School of ...
Overseen ByAlessandro Santin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, there is a requirement for a 'washout period' (time without taking certain medications) from prior systemic anti-neoplastic therapy, which is either five half-lives or four weeks, whichever is shorter.

What data supports the effectiveness of the drug Mirvetuximab Soravtansine (IMGN853) for endometrial cancer?

Research shows that Mirvetuximab Soravtansine is effective in treating aggressive endometrial cancers that overexpress the folate receptor alpha (FRα). In studies, it led to complete tumor resolution in certain endometrial cancer models and increased survival in uterine cancer models with high FRα expression.12345

What safety data exists for Mirvetuximab Soravtansine (IMGN853) in humans?

Mirvetuximab Soravtansine has been associated with low-grade eye and stomach-related side effects, which are generally mild and reversible. These side effects were observed in studies involving patients with ovarian cancer.12467

What makes the drug IMGN853 unique for treating endometrial cancer?

IMGN853 (Mirvetuximab Soravtansine) is unique because it specifically targets the folate receptor alpha (FRα), which is overexpressed in certain aggressive endometrial cancers. This targeted approach allows the drug to deliver a potent cancer-killing agent directly to the cancer cells, potentially improving outcomes for patients with FRα-positive tumors.14589

Research Team

Alessandro Santin, MD < Yale School of ...

Alessandro Santin

Principal Investigator

Yale University

Eligibility Criteria

This trial is for women with certain types of advanced endometrial cancer that have a protein called FRα. They must have tried ≤3 treatments, not be pregnant, agree to contraception, and can't have had certain heart issues, brain conditions or other serious health problems.

Inclusion Criteria

Have signed the informed consent form, and willing to adhere to the study visit schedule and other protocol requirements
My tumor is FRα-positive.
Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at least twelve weeks after the last dose of IMGN853
See 12 more

Exclusion Criteria

I have an ongoing eye condition affecting my cornea.
I do not have any serious illnesses or active infections.
I do not have serious heart or blood vessel problems.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive IMGN853 at a dose of 6 mg/kg administered intravenously once every 3 weeks until unacceptable toxicity or disease progression

Variable, based on individual response
Every 3 weeks (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years

Treatment Details

Interventions

  • Mirvetuximab Soravtansine (IMGN853)
Trial OverviewThe study tests the effectiveness and safety of a drug named Mirvetuximab Soravtansine (IMGN853) in patients with type II endometrial cancers overexpressing folate receptor alpha. It's for those who've had previous treatments but still show signs of cancer.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: IMGN853Experimental Treatment1 Intervention
IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)

Mirvetuximab Soravtansine (IMGN853) is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Elahere for:
  • Platinum-resistant epithelial ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer
🇪🇺
Approved in European Union as Elahere for:
  • Epithelial ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alessandro Santin

Lead Sponsor

Trials
4
Recruited
140+

ImmunoGen, Inc.

Industry Sponsor

Trials
33
Recruited
4,000+

Findings from Research

Mirvetuximab soravtansine is an antibody-drug conjugate that received FDA accelerated approval for treating recurrent platinum-resistant high-grade serous ovarian cancer (HGSOC), showing an overall response rate of 32.4% and a median duration of response of 6.9 months in the SORAYA trial.
The treatment has a favorable safety profile, with primarily low-grade ocular and gastrointestinal toxicities, making it a promising option for patients with high FRα expression in their tumors.
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.Porter, RL., Matulonis, UA.[2023]
In a phase III study involving 366 patients with platinum-resistant epithelial ovarian cancer, mirvetuximab soravtansine (MIRV) did not significantly improve progression-free survival compared to standard chemotherapy, but showed better outcomes in secondary measures for patients with high folate receptor alpha (FRα) expression.
MIRV demonstrated a more favorable safety profile, with fewer severe treatment-related adverse events and lower rates of dose reductions and treatment discontinuations compared to chemotherapy.
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.Moore, KN., Oza, AM., Colombo, N., et al.[2021]
Mirvetuximab soravtansine, an antibody-drug conjugate targeting the folate receptor alpha, has shown promising clinical activity in treating platinum-resistant ovarian cancer, which is known for poor outcomes with standard chemotherapy.
This treatment combines a targeted approach with the cytotoxic effects of a chemotherapy agent, potentially offering a new strategy to overcome drug resistance in ovarian cancer patients.
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.Gonzalez-Ochoa, E., Veneziani, AC., Oza, AM.[2023]

References

Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. [2023]
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. [2021]
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. [2023]
Mirvetuximab Soravtansine: First Approval. [2023]
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. [2020]
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. [2020]
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite. [2023]
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. [2019]
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. [2019]